Biogen and Eisai are expecting accelerated approval for an Alzheimer's disease drug in January.
Gilead Sciences is waiting for approval of a new HIV treatment that only needs to be taken twice a year.
Mirati Therapeutics could earn approval for an experimental lung cancer drug similar to one that is already generating hundreds of millions annually for Amgen.
